Multiple bispecific NK-cell engagers are in pre-clinical development and target NK-cell antigens such as NKG2D, CD16a, MICA, CD16a and CD200,NKp30, Nkp46 and myeloma cell antigens such as CS1, BCMA, CD38 (77–81). Here, TNFRSF17 is linked to plasma cell myeloma.